Literature DB >> 20161667

Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress.

Roy L Silverstein1.   

Abstract

Platelet hyper-reactivity and a systemic prothrombotic state are associated with atherosclerosis and other inflammatory conditions. CD36, a member of the Type 2 scavenger receptor family, is a multiligand pattern recognition receptor that recognizes specific oxidized phospholipids, molecules expressed on microbial pathogens, apoptotic cells, and cell-derived microparticles. Recent studies have demonstrated that CD36 binding to oxidized LDL or microparticles activates a specific signaling pathway that induces platelet activation. This pathway is activated in vivo in the setting of hyperlipidemia and oxidant stress. Genetic deletion of CD36 protects mice from pathological thrombosis associated with hyperlipidemia without any apparent effect on normal hemostasis. Targeting CD36 or its signaling pathway could potentially lead to the development of novel antithrombotic therapies for patients with atheroinflammatory disorders.

Entities:  

Year:  2009        PMID: 20161667      PMCID: PMC2819200          DOI: 10.2217/clp.09.57

Source DB:  PubMed          Journal:  Clin Lipidol        ISSN: 1758-4302


  148 in total

Review 1.  CD36-TSP-HRGP interactions in the regulation of angiogenesis.

Authors:  Roy L Silverstein; Maria Febbraio
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

2.  Gene expression in human NAFLD.

Authors:  Dario Greco; Anna Kotronen; Jukka Westerbacka; Oscar Puig; Perttu Arkkila; Tuula Kiviluoto; Saara Laitinen; Maria Kolak; Rachel M Fisher; Anders Hamsten; Petri Auvinen; Hannele Yki-Järvinen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-03       Impact factor: 4.052

3.  CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails.

Authors:  N Tao; S J Wagner; D M Lublin
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

4.  Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients.

Authors:  Verena Pihusch; Andreas Rank; Ruth Steber; Markus Pihusch; Rudolf Pihusch; Bettina Toth; Erhard Hiller; Hans-Jochem Kolb
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

5.  Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium.

Authors:  D M Knowles; B Tolidjian; C Marboe; V D'Agati; M Grimes; L Chess
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

6.  Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and cholesterol.

Authors:  Ariëtte van Bennekum; Moritz Werder; Stephen T Thuahnai; Chang-Hoon Han; Phu Duong; David L Williams; Philipp Wettstein; Georg Schulthess; Michael C Phillips; Helmut Hauser
Journal:  Biochemistry       Date:  2005-03-22       Impact factor: 3.162

7.  Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.

Authors:  V Pijuan-Thompson; J R Grammer; J Stewart; R L Silverstein; S F Pearce; G P Tuszynski; J E Murphy-Ullrich; C L Gladson
Journal:  Exp Cell Res       Date:  1999-05-25       Impact factor: 3.905

8.  Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.

Authors:  Arunima Ghosh; Wei Li; Maria Febbraio; Ricardo G Espinola; Keith R McCrae; Erin Cockrell; Roy L Silverstein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine.

Authors:  Fatiha Nassir; Brody Wilson; Xianlin Han; Richard W Gross; Nada A Abumrad
Journal:  J Biol Chem       Date:  2007-05-15       Impact factor: 5.157

10.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

View more
  7 in total

1.  CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin.

Authors:  Sinju Sundaresan; Rafiq Shahid; Terrence E Riehl; Rashmi Chandra; Fatiha Nassir; William F Stenson; Rodger A Liddle; Nada A Abumrad
Journal:  FASEB J       Date:  2012-12-11       Impact factor: 5.191

Review 2.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27

3.  Endothelial cell CD36 deficiency prevents normal angiogenesis and vascular repair.

Authors:  Lara Bou Khzam; Ni-Huiping Son; Adam E Mullick; Nada A Abumrad; Ira J Goldberg
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

4.  The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-15       Impact factor: 5.555

5.  The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration.

Authors:  Hiroaki Bessho; Shigeru Honda; Naoshi Kondo; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  Mol Vis       Date:  2012-01-18       Impact factor: 2.367

6.  Correlation of gene polymorphisms of CD36 and ApoE with susceptibility of Alzheimer disease: A case-control study.

Authors:  Li Zhou; Hai-Yan Li; Ji-Hui Wang; Zhe-Zhi Deng; Yi-Long Shan; Sha Tan; Yi-Hua Shi; Ming-Xing Zhang; San-Xin Liu; Bing-Jun Zhang; Ming-Fan Hong; Zheng-Qi Lu; Xu-Ming Huang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Human Placental Mesenchymal Stem/Stromal cells (pMSCs) inhibit agonist-induced platelet functions reducing atherosclerosis and thrombosis phenotypes.

Authors:  Abdullah Al Subayyil; Yasser S Basmaeil; Reem Alenzi; Tanvir Khatlani
Journal:  J Cell Mol Med       Date:  2021-09-18       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.